Premium Nahrungsergänzungsmittel | artgerecht

Cagrilintide – Mechanism, Use & Clinical Trials

Cagrilintide is a long-acting amylin analogue under investigation for the treatment of obesity and type 2 diabetes, reducing appetite and regulating blood sugar levels.

Regular tips about health Regular tips about health

Things worth knowing about "Cagrilintide"

Cagrilintide is a long-acting amylin analogue under investigation for the treatment of obesity and type 2 diabetes, reducing appetite and regulating blood sugar levels.

What is Cagrilintide?

Cagrilintide is an investigational, long-acting amylin analogue -- a synthetic peptide hormone structurally similar to the naturally occurring hormone amylin (also known as Islet Amyloid Polypeptide, or IAPP). Amylin is co-secreted with insulin by the beta cells of the pancreas and plays a key role in regulating blood glucose levels and satiety. Cagrilintide is being developed by the Danish pharmaceutical company Novo Nordisk and is currently being evaluated in clinical trials, including in combination with the GLP-1 receptor agonist semaglutide (under the project name CagriSema).

Indications

Cagrilintide is primarily being investigated for the following conditions:

Obesity: For weight reduction in adults with a body mass index (BMI) of 30 or above.
Type 2 diabetes mellitus: To improve glycaemic control in patients with insufficient blood sugar management.
Combination therapy: In conjunction with other agents such as semaglutide, to achieve synergistic effects on body weight and blood glucose.

Mechanism of Action

Cagrilintide mimics the action of the natural hormone amylin by binding to amylin receptors in the brain and peripheral tissues. Its key pharmacological effects include:

Slowing of gastric emptying: Food passes more slowly from the stomach into the small intestine, prolonging the feeling of fullness after meals.
Appetite suppression: Activation of amylin receptors in the hypothalamus -- the brain region controlling hunger and satiety -- reduces food intake.
Inhibition of glucagon secretion: Cagrilintide suppresses the release of glucagon, a hormone that raises blood sugar levels, thereby contributing to better glycaemic control.
Extended half-life: Compared to native amylin, cagrilintide has a significantly prolonged duration of action, enabling once-weekly subcutaneous administration.

Dosage and Administration

Cagrilintide is administered as a subcutaneous injection (under the skin). In clinical trials, it is typically given once weekly, simplifying treatment for patients. Doses of up to 2.4 mg per week have been investigated in the SCALE trials and CagriSema combination studies. As the compound is still under clinical development, no officially approved standard dosage has yet been established.

Clinical Trial Results

Phase 2 and Phase 3 studies have shown promising results for cagrilintide:

As a monotherapy, cagrilintide achieved significant weight loss compared to placebo.
In combination with semaglutide (CagriSema), particularly pronounced weight reductions were observed -- exceeding 20% of baseline body weight in some study arms.
The combination also demonstrated favourable effects on HbA1c (long-term blood glucose marker) and cardiovascular risk factors.

Side Effects

As with other peptide hormone analogues, the most common side effects of cagrilintide are gastrointestinal in nature and include:

Nausea
Vomiting
Diarrhoea
Constipation
Decreased appetite

These side effects typically occur at the start of treatment and diminish over time in most patients. More serious adverse events, such as pancreatitis (inflammation of the pancreas), have been reported in association with amylin analogues and are being carefully monitored in ongoing trials.

Treatment Context and Outlook

Cagrilintide represents part of a new generation of combination therapies targeting obesity and type 2 diabetes. By simultaneously activating multiple hormonal pathways -- specifically the amylin and GLP-1 signalling axes -- this approach aims to achieve superior efficacy compared to single-agent treatments. If ongoing Phase 3 trials are successful, cagrilintide could be submitted for regulatory approval as part of a fixed-dose combination with semaglutide in the coming years.

References

Enebo LB et al. - Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for weight management. The Lancet (2021). https://doi.org/10.1016/S0140-6736(21)01238-X
Novo Nordisk - CagriSema Phase 3 Clinical Trial Program (REDEFINE). Novo Nordisk Pipeline Information (2023). https://www.novonordisk.com
Dehestani B et al. - Amylin as a potential target for the treatment of obesity and metabolic disorders. Diabetes, Obesity and Metabolism (2022). https://doi.org/10.1111/dom.14720

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.